Around 0.75 million babies worldwide suffer from moderate or severe hypoxic-ischemic
encephalopathy (HIE) each year resulting in around 400,000 babies with …

Hypothermia therapy is an old and important method of neuroprotection. Until now, many
neurological diseases such as stroke, traumatic brain injury, intracranial pressure elevation …

Rationale: The neuroinflammation is necessary for glial group initiation and clearance of
damaged cell debris after nerve injury. However, the proinflammatory polarization of …

Hypoxic-ischemic encephalopathy (HIE) is a brain lesion caused by inadequate blood
supply and oxygen deprivation, often occurring in neonates. It has emerged as a grave …

In term and near-term neonates with neonatal encephalopathy, therapeutic hypothermia
protocols are well established. The current focus is on how to improve outcomes further and …

ABSTRACT Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however,
its function in the brain is not well studied. In this systematic review, we aimed to analyze the …

Background Despite considerable efforts, ischemic stroke (IS) remains a challenging clinical
problem. Therefore, the discovery of effective therapeutic and targeted drugs based on the …

Therapeutic hypothermia is now proven to reduce death or disability in term and near‐term
born infants with moderate to severe hypoxic‐ischemic encephalopathy. Nevertheless …

Neonatal hypoxic–ischaemic brain damage is a leading cause of child mortality and
morbidity, including cerebral palsy, epilepsy, and cognitive disabilities. The majority of …

Epidemiological analyses indicate that type 2 diabetes mellitus (T2DM) is a risk factor for
Alzheimer's disease (AD). They share common pathophysiological mechanisms. Thus, it has …